The South Carolina Department of Commerce (S.C. Commerce) today announced the completion of final approvals for Octapharma’s first U.S. manufacturing and production facility in York County. The $1.5 billion investment is projected to bring more than 1,500 jobs to Rock Hill, and marks a significant milestone as the biopharmaceutical manufacturer moves forward with establishing operations in South Carolina, further strengthening the state’s rapidly growing life sciences industry.

Headquartered in Lachen, Switzerland, Octapharma has more than 40 manufacturing and office sites worldwide, with production facilities in Austria, France, Germany and Sweden. The company, which was founded in 1983, develops and produces medicines based on proteins derived from human cell lines and human plasma.  

This new facility will be located in Rock Hill’s Palmetto Research Park and include an administrative campus for Octapharma’s plasma donation operations. Manufacturing operations are expected to commence in the mid-2030s, with corporate offices planned for 2028.

City of Rock Hill Mayor John Gettys said, “Working with the S.C. Department of Commerce, SCbio and the Charlotte Regional Business Alliance, we pursued a development strategy designed to deliver lasting value for our residents, businesses, educational institutions and public-sector partners. Octapharma is exactly that kind of investment, creating high-quality jobs across all education levels for generations to come. We are honored to welcome Octapharma to Rock Hill.”

In June, Novant Health announced a medical campus on approximately 25 acres of the site. Palmetto Research Park, through the Novant Health announcement and Octapharma project, represents over $1.8 billion dollars of investment, over 1,800 jobs and average annual salaries over $100,000. The City welcomes additional developments throughout the Palmetto Research Region, building on the values of these two outstanding companies.